- 18-month duration of response (DOR) data from ENVISION, and integrated patient-reported outcomes (PROs) from UGN-102-treated patients in OPTIMA II, ATLAS and ENVISION in low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC)
- Long-term outcomes from the OPTIMA II Phase 2B study of UGN-102
- Sub-analysis from a long-term follow-up study to the OLYMPUS trial of JELMYTO® (mitomycin) for pyelocalyceal solution
- Results of a Phase 1 dose escalation study for UGN-301
“We are thrilled to present the 18-month DOR data on UGN-102, along with additional data on JELMYTO and our investigational drug UGN-301 (zalifrelimab) an anti-CTL4 antibody in development for the treatment of recurrent non-muscle invasive bladder cancer, at the AUA Annual Meeting,” said Mark Schoenberg, Chief Medical Officer, UroGen. “These data highlight the potential of our portfolio to offer significant advancements in the treatment of urothelial cancers.”Key details of UGN-102, JELMYTO and UGN-301 abstracts accepted by AUA:
UroGen is a Founders’ Circle Sponsor of the AUA Innovation Nexus Conference
UroGen’s President and Chief Executive Officer, Liz Barrett, will participate in a Showcase Panel discussion on April 25, alongside exciting urology startups that span the globe and are developing products—devices, artificial intelligence platforms, diagnostic tests, etc.—covering a variety of urologic issues such as prostate and bladder cancer, kidney injuries, fertility testing, nocturnal enuresis, overactive bladder, and interstitial cystitis. Liz will also take part in the Founders’ Circle Awards Presentation.
The AUA Innovation Nexus is a powerful forum to advance urologic discovery to solutions that improve patient care and save lives. Register here: https://auanexus.org/innovation-nexus-conference/registration.
Source: UroGen Pharma Ltd. (2025). UroGen Announces Data Presentations at the American Urological Association 2025 Annual Meeting Highlighting Emerging Evidence Supporting Our Portfolio for Urothelial Cancers [Press release]. https://investors.urogen.com/news-releases/news-release-details/urogen-announces-data-presentations-american-urological.